Hagens Berman today announced that newly published materials for the upcoming Food and Drug Administration’s (FDA) Circulatory System Devices Panel meeting raise new issues regarding Abiomed, Inc. (NASDAQ: ABMD) (“Abiomed”) discussions with the FDA concerning the safety and effectiveness of the Impella 2.5 for high-risk PCI and Abiomed’s marketing practices. The firm also advises investors who purchased Abiomed stock between Aug. 5, 2011 and Oct. 31, 2012 (the “Class Period”) of the Jan. 15, 2013 deadline for moving to be lead plaintiff in a proposed class-action lawsuit against Abiomed regarding alleged securities law violations.